GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Recbio Technology Co 2179.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

4.00

0.00%

Close of 5 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jiangsu Recbio Technology Co

Its shares trade on HKEX under the ticker 2179.HK. It has been listed since 31 March 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥14.4m and a net loss of CN¥692.3m. At that date it held total assets of CN¥2.05bn and shareholders' equity of CN¥822.2m.

Jiangsu Recbio Technology Co., Ltd. engages in the research and development of vaccines. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2022-03-31. The firm has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The firm also involves in the development of Covid-19 vaccines. The firm mainly distributes products within domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
31 Mar 2022
Employees
434
Website
recbio.cn ↗

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company focuses on vaccine R&D with clinical and pre-clinical stage pipelines.
  • Headquartered in Taizhou, Jiangsu with 434 employees.
  • IPO completed on 2022-03-31.

Weaknesses

  • Limited to domestic market distribution only.
  • No mention of international market presence or expansion plans.
  • No details provided on financial performance or revenue sources.

Opportunities

  • Potential growth in HPV vaccine market with multiple pipeline candidates.
  • Covid-19 vaccine development could address global health needs.
  • IPO in 2022 may facilitate future funding for R&D expansion.

Threats

  • Dependence on domestic market limits revenue diversification.
  • Competition in vaccine development sector may impact market share.
  • No information on regulatory approvals for pipeline products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.